Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

295

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Positive
HER2 Positive Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Fulvestrant
OTHER: Laboratory Biomarker Analysis
DRUG: Lapatinib Ditosylate
OTHER: Placebo Administration

Sponsor

National Cancer Institute (NCI)